Collagenase 3 - Pipeline Review, H2 2020
Collagenase 3 - Pipeline Review, H2 2020
SUMMARY
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) pipeline Target constitutes close to 5 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes. The latest report Collagenase 3 - Pipeline Review, H2 2020, outlays comprehensive information on the Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Collagenase-3 (MMP13) is a member of the matrix metalloproteinase (MMP) family of neutral endopeptidases. It plays a role in the degradation of extracellular matrix proteins including fibrillar collagen, fibronectin, TNC and ACAN, wound healing, tissue remodeling, cartilage degradation, bone development, bone mineralization and ossification. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 2 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Musculoskeletal Disorders, Cardiovascular, Central Nervous System, Genetic Disorders, Infectious Disease and Respiratory which include indications Osteoarthritis, Allergic Asthma, Alphavirus Infections, Arthralgia (Joint Pain), Arthritis, Chikungunya Fever, Congestive Heart Failure (Heart Failure), Edema, Knee Osteoarthritis, Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ), Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ), Myocardial Infarction, Osteoarthritis Pain and Seasonal Allergic Rhinitis.
Furthermore, this report also reviews key players involved in Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) pipeline Target constitutes close to 5 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes. The latest report Collagenase 3 - Pipeline Review, H2 2020, outlays comprehensive information on the Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Collagenase-3 (MMP13) is a member of the matrix metalloproteinase (MMP) family of neutral endopeptidases. It plays a role in the degradation of extracellular matrix proteins including fibrillar collagen, fibronectin, TNC and ACAN, wound healing, tissue remodeling, cartilage degradation, bone development, bone mineralization and ossification. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 2 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Musculoskeletal Disorders, Cardiovascular, Central Nervous System, Genetic Disorders, Infectious Disease and Respiratory which include indications Osteoarthritis, Allergic Asthma, Alphavirus Infections, Arthralgia (Joint Pain), Arthritis, Chikungunya Fever, Congestive Heart Failure (Heart Failure), Edema, Knee Osteoarthritis, Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ), Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ), Myocardial Infarction, Osteoarthritis Pain and Seasonal Allergic Rhinitis.
Furthermore, this report also reviews key players involved in Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.)
- The report reviews Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics and enlists all their major and minor projects
- The report assesses Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Overview
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Companies Involved in Therapeutics Development
Aquilus Pharmaceuticals Inc
Paradigm Biopharmaceuticals Ltd
Pfizer Inc
Pharmahungary Group
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Drug Profiles
pentosan polysulfate sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-152 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Proteins for Rheumatoid Arthritis and Osteoarthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MMP 2,9 and 13 for Myocardial Infarction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MMP-13 for Osteoarthritis Pain and Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Dormant Products
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Discontinued Products
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Product Development Milestones
Featured News & Press Releases
Oct 01, 2020: Zilosul reduces pain in patients with knee osteoarthritis
Sep 28, 2020: Paradigm’s clear path towards Zilosul’s OA phase 3 clinical trial and product registration in Europe
Aug 11, 2020: Paradigm receives critical approvals and feedback from agencies to progress MPS clinical and commercial development
Jul 30, 2020: Paradigm reports: 65% Pain reduction in OA patients treated under the US FDA Expanded Access Program
Apr 30, 2020: Paradigm reports: Under the US FDA Expanded Access Program treatment is completed for all of the ten planned patients. Paradigm granted Orphan Status by US FDA for MPS-I
Apr 06, 2020: Paradigm reports very encouraging realworld data ahead of its phase 3 OA Clinical Trial
Feb 21, 2020: Paradigm reports positive pre-IND meeting with US FDA
Feb 18, 2020: Paradigm reports: first patient dosed in USA under FDA approved expanded access program
Feb 13, 2020: Paradigm presents MPS VI poster at the World MPS Symposium in Orlando, Florida
Sep 30, 2019: Peer-reviewed publication confirms Paradigms ground-breaking discovery regarding new MOA for PPS
Sep 10, 2019: Paradigms first FDA IND is cleared within the 30-day review period
Aug 29, 2019: Paradigm discovers Zilosulo (iPPS) protects cartilage in knee osteoarthritis
Jun 04, 2019: Paradigm reports successful ross river phase 2a clinical trial
May 28, 2019: Paradigm reports positive RWE data for knee osteoarthritis therapeutic
Apr 16, 2019: Paradigm’s knee osteoarthritis study meets secondary endpoints
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Figures
Introduction
Global Markets Direct Report Coverage
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Overview
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Companies Involved in Therapeutics Development
Aquilus Pharmaceuticals Inc
Paradigm Biopharmaceuticals Ltd
Pfizer Inc
Pharmahungary Group
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Drug Profiles
pentosan polysulfate sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-152 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Proteins for Rheumatoid Arthritis and Osteoarthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MMP 2,9 and 13 for Myocardial Infarction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MMP-13 for Osteoarthritis Pain and Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Dormant Products
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Discontinued Products
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Product Development Milestones
Featured News & Press Releases
Oct 01, 2020: Zilosul reduces pain in patients with knee osteoarthritis
Sep 28, 2020: Paradigm’s clear path towards Zilosul’s OA phase 3 clinical trial and product registration in Europe
Aug 11, 2020: Paradigm receives critical approvals and feedback from agencies to progress MPS clinical and commercial development
Jul 30, 2020: Paradigm reports: 65% Pain reduction in OA patients treated under the US FDA Expanded Access Program
Apr 30, 2020: Paradigm reports: Under the US FDA Expanded Access Program treatment is completed for all of the ten planned patients. Paradigm granted Orphan Status by US FDA for MPS-I
Apr 06, 2020: Paradigm reports very encouraging realworld data ahead of its phase 3 OA Clinical Trial
Feb 21, 2020: Paradigm reports positive pre-IND meeting with US FDA
Feb 18, 2020: Paradigm reports: first patient dosed in USA under FDA approved expanded access program
Feb 13, 2020: Paradigm presents MPS VI poster at the World MPS Symposium in Orlando, Florida
Sep 30, 2019: Peer-reviewed publication confirms Paradigms ground-breaking discovery regarding new MOA for PPS
Sep 10, 2019: Paradigms first FDA IND is cleared within the 30-day review period
Aug 29, 2019: Paradigm discovers Zilosulo (iPPS) protects cartilage in knee osteoarthritis
Jun 04, 2019: Paradigm reports successful ross river phase 2a clinical trial
May 28, 2019: Paradigm reports positive RWE data for knee osteoarthritis therapeutic
Apr 16, 2019: Paradigm’s knee osteoarthritis study meets secondary endpoints
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indication, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products under Investigation by Universities/Institutes, H2 2020
Products under Investigation by Universities/Institutes, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by Aquilus Pharmaceuticals Inc, H2 2020
Pipeline by Paradigm Biopharmaceuticals Ltd, H2 2020
Pipeline by Pfizer Inc, H2 2020
Pipeline by Pharmahungary Group, H2 2020
Dormant Products, H2 2020
Dormant Products, H2 2020 (Contd..1), H2 2020
Discontinued Products, H2 2020
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indication, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products under Investigation by Universities/Institutes, H2 2020
Products under Investigation by Universities/Institutes, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by Aquilus Pharmaceuticals Inc, H2 2020
Pipeline by Paradigm Biopharmaceuticals Ltd, H2 2020
Pipeline by Pfizer Inc, H2 2020
Pipeline by Pharmahungary Group, H2 2020
Dormant Products, H2 2020
Dormant Products, H2 2020 (Contd..1), H2 2020
Discontinued Products, H2 2020
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020
